Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Asymmetric synthesis of benzoxazinones

A compound and asymmetric technology, applied in the direction of drug combination, organic chemistry, organic active ingredients, etc., can solve instability, expensive and other problems

Inactive Publication Date: 2000-02-23
DU PONT PHARMA CO
View PDF3 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] To this end, the present invention provides a novel benzylation method using acid-catalyzed benzyl alcohols instead of the corresponding benzyl chloride analogues, which are relatively more expensive and unstable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Asymmetric synthesis of benzoxazinones

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0031] In a preferred embodiment, the compound of formula (VI) wherein X is Cl and A is -CF 3 The preparation methods include:

[0032] (1) In the presence of a suitable acid catalyst, the compound of formula (I) is reacted with the compound of formula (VII), wherein: R 1 for H, C 1-6 Alkyl or C 1-6 Alkylcarbonyl, R 2 for H, R 3 for H, -CH 3 ,-CH 2 CH 3 or by 0-3 R 12 Substituted phenyl, R 4 , R 5 , R 4a , R 5a with R 6 independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Alkylthio, and R 12 for H, C 1-6 Alkyl, C 1-6 Alkoxy or C 1-6 Alkylthio; generate formula (II) compound;

[0033] (2)(a) reacting 1R, 2S-pyrrolidinyl norephedrine with n-hexyl lithium and cyclopropylacetylene to form a mixture of 1R, 2S-pyrrolidinyl norephedrine and lithium cyclopropylacetylide, and

[0034] (b) reacting the mixture of step (2)(a) with the compound of formula (II) to generate the compound of formula (III);

[0035] (3) reacting the compound of formula (II...

Embodiment 1

[0169] Preparation of N-(4-chlorophenyl)-2,2-dimethylpropanamide

[0170] 4-Chloroaniline (52.7kg, 413mol) was dissolved in a mixture of tert-butyl methyl ether (180kg), 30% aqueous sodium hydroxide solution (61.6kg, 463mol) and water (24.2kg), then cooled to 15°C. To the resulting slurry was added trimethylacetyl chloride (52.2 kg, 448 mol) over 1 hour while maintaining the temperature below 40°C. After stirring at 30°C for 30 minutes, the slurry was cooled to -10°C for 2 hours. The product was collected by filtration, washed with a solution of water (90) dimethanol (10) (175 kg), and dried in vacuo to give 85 kg (97% yield) of the title compound as a crystalline solid, mp. 152-153°C.

[0171] 1 H NMR (300MHz, CCDCl 3 )δ7.48(d, J=9Hz, 2H)7.28(d, J=9Hz, 2H); 13 C NMR (75MHz, CDCl 3 )d 176.7, 136.6, 129.1, 128.9, 121.4, 39.6, 27.6.

[0172] Preparation of N-(4-fluorophenyl)-2,2-methylpropanamide

[0173] A person familiar with the field of organic synthesis understands t...

Embodiment 2

[0175] Preparation of 4-chloro-2-trifluoroacetanilide hydrochloride hydrate

[0176] N-(4-chlorophenyl)-2,2-dimethylpropanamide (36.7kg, 173mol) was added to a solution of TMEDA (20.2kg, 174mol) in anhydrous tert-butyl methyl ether (271.5kg), and Cool to -20°C. To this cooled slurry was added 2.7N n-butyl lithium in hexane (101.9 kg, 393 mol) while maintaining the temperature below 5°C. After cooling at 0-5°C for 2 hours, the solution was cooled to below -15°C and reacted rapidly with ethyl trifluoroacetate (34.5kg, 243mol). After 10 minutes the resulting solution was poured into 3N HCl (196 L, 589 mol) keeping the temperature below 25 °C. After removal of the aqueous phase, the organic solution was concentrated and about 200 L of solvent was distilled off. Acetic acid (352 kg) was added while 325 kg of solvent was distilled off at 100 mm Hg. After the solution was cooled to 30°C, 12N HCl (43.4 kg, 434 mol) was added and the mixture was heated to 65-70°C for 4 hours. The ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides novel methods for the asymmetric synthesis of (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one of formula (VI-i) which is useful as a human immunodeficiency virus (HIV) reverse transcriptase inhibitor.

Description

field of invention [0001] The present invention provides the asymmetric synthesis of (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazine-2- A new approach to ketones, compounds that can be used as human immunodeficiency virus (HIV) reverse transcriptase inhibitors. Background of the invention [0002] Reverse transcription is a common feature of retroviral replication. Viral replication requires a virally encoded reverse transcriptase to generate a DNA replica with viral sequences by retroviral RNA genome. Because inhibition of virally encoded reverse transcriptase interrupts viral replication, reverse transcriptase is clinically a relevant target for chemotherapy of retroviral infections. [0003] Many compounds are effective in treating human immunodeficiency virus (HIV), a retrovirus that progressively destroys the human immune system, resulting in AIDS. Drugs known to be effective in the treatment by inhibiting HIV reverse transcriptase ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/535A61P31/18A61P43/00C07D265/18
CPCC07D265/18Y02P20/55A61P31/18A61P43/00
Inventor M·E·皮尔斯A·乔德赫里小R·L·帕森斯
Owner DU PONT PHARMA CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com